Breakthroughs in genomics have begun to unravel the genetic architecture of schizophrenia risk, providing methods for quantifying schizophrenia polygenic risk based on common genetic variants. Our ...

The inclusion of neurocognitive end points in clinical trials of patients with CNS tumors is increasing. Neurocognitive end points are used to understand what cognitive problems exist before treatment ...

A study published this week in the Annals of Internal Medicine by Sneller and colleagues compared 189 people who had recovered from Covid-19—many of whom reported symptoms of Long Covid—to a control ...

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% One hundred thirty-nine infants with a newly diagnosed CNS ...